基于真实世界数据的注射用紫杉醇(白蛋白结合型)药学监护路径研究OACSTPCD

OBJECTIVE:To establish the pharmaceutical care pathways of nanoparticle albumin bound paclitaxel(nab-PTX),so as to provide reference for clinical rational drug use.METHODS:Data of patients who used nab-PTX from Jan.2020 to Jun.2023 in the hospital were retrospectively analyzed and evaluated.The pharmaceutical care pathways of rational use of nab-PTX was established based on the instructions of nab-PTX,evidence-based medicine,and the real-world data of nab-PTX use in the hospital.RESULTS:Data analysis of 279 patients included in this study showed that 42 cases of metastatic breast were in line with the drug indications of nab-PTX,and 237 cases(84.9%)were off-label.There were 209 off-label cases with evidence-based medical evidence(including cervical cancer,pancreatic cancer,stomach cancer,non-small cell lung cancer,nasopharyngeal cancer,ovarian cancer or fallopian tube cancer,esophageal cancer,endometrial cancer,and cholangiocarcinoma),which were evaluated as rational drug use.However,some off-label cases(oral cancer,mediastinal tumor,bone carcinoma,soft-tissue carcinoma,prostatic cancer,and malignant duodenal neoplasm)were evaluated as irrational due to insufficient evidence-based medical evidence.The most common adverse drug reactions of nab-PTX were myelosuppression and peripheral neuropathy,which were consistent with the drug instructions.The pharmaceutical care pathways of nab-PTX were established from various aspects,including pre-chemotherapy,chemotherapy,post-chemotherapy and follow-up.CONCLUSIONS:Off-label drug use of nab-PTX is common,and the management for application of nab-PTX should be strengthened.The development of pharmaceutical care pathways of nab-PTX can improve the work efficiency of pharmacists and ensure the safe and rational drug use of cancer patients.